RxDoctor Payments Data

James Agresti, DO

Internal Medicine · Nutley, NJNPI 1578511135

Payments from drug & device makers

$7,300in general payments, 2019–2025

Across 521 payments — averaging $14.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$722
  • Lilly USA, LLC$608
  • Novo Nordisk$587
  • Boehringer Ingelheim$477
  • Amgen$401
  • Sanofi-aventis U.S. LLC$333
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$7,300100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca50$722
Lilly USA, LLC45$608
Novo Nordisk44$587
Boehringer Ingelheim34$477
Amgen30$401
Sanofi-aventis U.S. LLC25$333
Pfizer24$324
Johnson & Johnson(2 entities)17$230
Kowa Pharmaceuticals America, Inc.15$205
Sunovion Pharmaceuticals Inc.14$199
Exact Sciences8$195
Otsuka America Pharmaceutical, Inc.13$184
GSK13$181
Amarin Pharma, Inc.14$177
Arbor Pharmaceuticals, Inc.13$168
Takeda Pharmaceuticals U.S.A., Inc.12$158
AbbVie(2 entities)10$158
Novartis10$157
Sumitomo Pharma America, Inc.11$146
Azurity Pharmaceuticals, Inc.9$137
Almatica Pharma LLC9$130
Bayer9$123
Lundbeck LLC8$121
Idorsia Pharmaceuticals US Inc6$86
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$80
Eisai Inc.6$78
Astellas Pharma US Inc5$77
E.r. Squibb & Sons, L.L.C.4$72
Xeris Pharmaceuticals, Inc.4$59
Axsome Therapeutics, Inc.4$59
Fidia Pharma USA Inc.4$58
Scilex Pharmaceuticals Inc.4$48
Antares Pharma, Inc.3$41
Mannkind Corporation3$39
Althera Pharmaceuticals LLC3$35
Braeburn Inc.2$32
Ardelyx, Inc.2$32
Avanir Pharmaceuticals, Inc.2$29
Endo Pharmaceuticals Inc.2$28
IBSA Pharma Inc.2$26
Nabriva Therapeutics, PLC2$26
Urovant Sciences Inc2$26
Merck2$26
Sanofi Pasteur Inc.1$18
Avion Pharmaceuticals1$17
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$15
Teva Pharmaceuticals USA, Inc.1$15
Nestle Healthcare Nutrition Inc.1$15
Sun Pharmaceutical Industries Inc.1$14
Acadia Pharmaceuticals Inc1$14
Phathom Pharmaceuticals, Inc.1$14
Paratek Pharmaceuticals, Inc.1$13
Abbott1$13
Melinta Therapeutics, LLC1$12
Ironwood Pharmaceuticals, Inc1$12
Dexcom, Inc.1$12
Alfasigma USA, Inc.1$12
Esperion Therapeutics, Inc.1$12
Acerus Pharmaceuticals Corporation1$12

How this compares

$7,300 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$591,222
Medicare patients
632
Services billed
6,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban624$232,277
OzempicSemaglutide127$127,915
MounjaroTirzepatide94$107,785
JardianceEmpagliflozin153$85,031
TrulicityDulaglutide55$70,784
GlyxambiEmpagliflozin/Linagliptin101$68,136
FarxigaDapagliflozin Propanediol115$67,896
JanuviaSitagliptin Phosphate110$59,558
Trijardy XrEmpaglifloz/Linaglip/Metformin58$44,350
AtivanLorazepam11$44,230
XifaxanRifaximin24$38,744
LivaloPitavastatin Calcium52$37,566
EntrestoSacubitril/Valsartan85$33,848
XareltoRivaroxaban92$32,880
RybelsusSemaglutide24$28,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta, Jentadueto$477$252,379407 claims
PfizerEliquis$324$232,277624 claims
Lilly USA, LLCMounjaro, Trulicity$608$178,569149 claims
Novo NordiskOzempic, Rybelsus$587$156,017151 claims
AstraZenecaFarxiga, Breztri Aerosphere, Nexium$722$90,182142 claims
MerckJanuvia$26$59,558110 claims
Johnson & JohnsonXarelto, Invokana$230$43,082105 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$80$38,74424 claims
Kowa Pharmaceuticals America, Inc.Livalo$205$37,56652 claims
NovartisEntresto$157$33,84885 claims
GSKArexvy, Trelegy Ellipta$181$24,64458 claims
AbbVieLinzess$158$21,35331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Nutley

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →